Commiphora molmol

Commiphora molmol, commonly called myrrh, is a resinous gum containing sesquiterpenes (including furanoeudesma-1,3-diene) and terpenoids that drive its anti-inflammatory and antimicrobial actions. Its oleo-gum-resin interacts with opioid receptors and inhibits pro-inflammatory mediators, forming the basis of its traditional and emerging clinical applications.

Origin & History

Commiphora molmol (myrrh) is an oleo-gum-resin obtained from the stem bark of trees in the Burseraceae family native to East Africa (Somalia, Ethiopia) and the Arabian Peninsula. The resin is collected by making incisions in the trunk, allowing the exudate to harden into tears, which are then extracted mechanically without chemical processing.

Historical & Cultural Context

Myrrh has been used for over 2,000 years in traditional medicine systems including Ayurvedic, Unani, and Middle Eastern/Ancient Egyptian practices for treating wounds, mouth ulcers, inflammation, and microbial infections. The EMA recognizes traditional herbal medicinal product status based on 30+ years of safe use in the EU.

Health Benefits

• Minor mouth ulcers and oral inflammation - Traditional use recognized by EMA for oromucosal application (traditional evidence)
• Antimicrobial activity - Preclinical studies show effectiveness against S. aureus (MIC 0.18-2.8 µg/ml), E. coli, and C. albicans (preliminary evidence)
• Anti-inflammatory effects - Reduces IL-6 and IL-8 production in gingival fibroblasts at 0.00001-0.001% concentrations (preliminary evidence)
• PGE2 suppression - Inhibits prostaglandin E2 production in fibroblasts without affecting NF-κB activation (preliminary evidence)
• Genoprotective effects - Animal studies show 45% reduction in lead-induced chromosomal aberrations (preliminary evidence)

How It Works

The sesquiterpene furanoeudesma-1,3-diene binds to opioid receptors, contributing to analgesic and anti-inflammatory effects. Myrrh's terpenoid fraction inhibits NF-κB signaling, suppressing downstream cytokines including TNF-α and IL-6. Additionally, the resin's volatile oil disrupts microbial cell membrane integrity, accounting for its broad-spectrum antimicrobial activity against S. aureus (MIC 0.18–2.8 µg/ml), E. coli, and Candida albicans.

Scientific Research

No human clinical trials or meta-analyses were identified in the research dossier. The EMA/HMPC assessments indicate insufficient clinical data for well-established use, with support limited to traditional use for minor oral conditions. All efficacy data comes from preclinical studies including antimicrobial assays and cell culture models.

Clinical Summary

Evidence for Commiphora molmol is largely preclinical and based on traditional use recognized by the European Medicines Agency (EMA) for oromucosal applications such as minor mouth ulcers and gingival inflammation. In vitro studies demonstrate consistent antimicrobial activity against gram-positive and gram-negative bacteria as well as fungi, though human randomized controlled trials are limited in number and sample size. One small clinical study examining myrrh-based mouthwash showed measurable reductions in plaque and gingival indices, but larger, well-controlled trials are needed to confirm efficacy and establish standardized dosing. Overall, evidence quality is classified as traditional or preliminary, and robust phase III clinical data are not yet available.

Nutritional Profile

Commiphora molmol (myrrh) is a resin-gum exudate, not a nutritional food ingredient, so conventional macronutrient profiling is not applicable in the traditional sense. However, its chemical composition is well-characterized: Resin fraction (25-40% of dry weight) contains terpenoids including sesquiterpenes (α-bisabolol, furanoeudesma-1,3-diene, lindestrene) and triterpenes (α- and β-amyrin, taraxasterol); Gum fraction (57-65% of dry weight) is a water-soluble polysaccharide composed of arabinose, galactose, xylose, and glucuronic acid residues — contributing minor carbohydrate content but not nutritionally significant at typical doses; Essential oil fraction (2-8% of dry weight) contains sesquiterpene hydrocarbons (curzerene ~17%, β-elemene, δ-elemene) and furanosequiterpenes (furanodiene, furanodienone); Bioactive phenolic compounds include eugenol and ferulic acid at trace concentrations (<0.1%); Proteins and lipids are negligible (<1% combined); No clinically relevant vitamins or dietary minerals are present at meaningful concentrations; Typical therapeutic preparations use 1-5% myrrh tincture or dry extract equivalent to 300-600 mg crude resin; Bioavailability of terpenoid actives is moderate, enhanced by lipid-based carriers; oromucosal application bypasses first-pass metabolism, improving local bioavailability for oral health applications.

Preparation & Dosage

Tincture (1:5 in 90% ethanol) for oromucosal or cutaneous use in treating minor mouth ulcers and inflammation. No specific daily doses are established in clinical studies. Product must comply with European Pharmacopoeia monograph 01/2008:1349. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Frankincense, propolis, sage, chamomile, echinacea

Safety & Interactions

Commiphora molmol is generally well tolerated at typical oromucosal doses, but may cause allergic contact dermatitis in sensitized individuals, and topical preparations can occasionally produce localized burning or irritation. It should be avoided during pregnancy, as myrrh has historically demonstrated uterotonic properties that may stimulate uterine contractions. Myrrh may interact with anticoagulants such as warfarin by potentially altering clotting parameters, and caution is warranted in patients taking hypoglycemic agents given preliminary evidence of blood glucose-lowering activity. Patients with known resin or Burseraceae family allergies should avoid use entirely.